Price
Financials
Standalone, Rs crore| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 150 | 172 | 164 | 138 | 166 | 160 | 198 | 186 | 186 | 197 | 202 | 194 |
| Expenses | 132 | 148 | 145 | 127 | 149 | 145 | 179 | 176 | 174 | 178 | 182 | 178 |
| Operating Profit | 18 | 24 | 19 | 11 | 17 | 15 | 19 | 10 | 12 | 19 | 20 | 16 |
| OPM % | 12% | 14% | 12% | 8% | 10% | 9% | 9% | 6% | 6% | 10% | 10% | 8% |
| Other Income | 2 | 4 | 3 | 4 | 3 | 1 | 1 | 3 | 1 | 2 | -1 | 3 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 2 | 2 | 2 | 2 | 2 | 2 | 3 | 3 | 3 | 3 | 3 | 2 |
| Profit before tax | 18 | 25 | 20 | 12 | 18 | 13 | 17 | 11 | 10 | 18 | 16 | 17 |
| Tax % | 23% | 24% | 22% | 22% | 17% | 22% | 28% | 24% | 23% | 25% | 25% | 32% |
| Net Profit | 14 | 19 | 15 | 10 | 15 | 10 | 12 | 8 | 8 | 13 | 12 | 11 |
| EPS in Rs | 1.38 | 1.91 | 1.53 | 0.95 | 1.50 | 1.03 | 1.24 | 0.83 | 0.76 | 1.34 | 1.17 | 1.14 |
| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 326 | 206 | 238 | 321 | 307 | 432 | 487 | 527 | 647 | 662 | 772 | 779 |
| Expenses | 289 | 183 | 220 | 291 | 284 | 387 | 439 | 476 | 571 | 600 | 709 | 712 |
| Operating Profit | 38 | 23 | 18 | 30 | 23 | 45 | 47 | 52 | 76 | 62 | 62 | 67 |
| OPM % | 12% | 11% | 8% | 9% | 8% | 10% | 10% | 10% | 12% | 9% | 8% | 9% |
| Other Income | 4 | 8 | 7 | 5 | 4 | 11 | 5 | 6 | 12 | 9 | 4 | 5 |
| Interest | 1 | 1 | 0 | 1 | 1 | 2 | 2 | 1 | 1 | 1 | 1 | 0 |
| Depreciation | 2 | 2 | 2 | 2 | 7 | 15 | 12 | 10 | 9 | 9 | 11 | 11 |
| Profit before tax | 38 | 28 | 23 | 32 | 19 | 39 | 39 | 47 | 78 | 61 | 54 | 60 |
| Tax % | 32% | 27% | 29% | 28% | 25% | 26% | 22% | 24% | 23% | 22% | 24% | |
| Net Profit | 26 | 20 | 17 | 23 | 14 | 28 | 31 | 36 | 60 | 47 | 41 | 44 |
| EPS in Rs | 2.57 | 2.00 | 1.65 | 2.33 | 1.43 | 2.84 | 3.05 | 3.61 | 5.99 | 4.73 | 4.10 | 4.41 |
| Dividend Payout % | 24% | 31% | 42% | 29% | 48% | 26% | 29% | 28% | 21% | 16% | 37% |
| 10 Years | 5 Years | 3 Years | TTM | 1 Year | Last Year | |
|---|---|---|---|---|---|---|
| Compounded Sales Growth | 9% | 12% | 14% | 10% | ||
| Compounded Profit Growth | 4% | 10% | 3% | -4% | ||
| Stock Price CAGR | 5% | 9% | 11% | 8% | ||
| Return on Equity | 13% | 14% | 14% | 11% |
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 4 | 13 | 13 | 13 | 13 | 13 | 25 | 25 | 25 | 25 | 25 | 50 |
| Reserves | 97 | 107 | 128 | 137 | 152 | 150 | 166 | 189 | 216 | 266 | 301 | 302 |
| Borrowings | 0 | 2 | 0 | 2 | 4 | 45 | 14 | 4 | 1 | 3 | 11 | 0 |
| Other Liabilities | 67 | 71 | 48 | 57 | 71 | 119 | 128 | 129 | 163 | 152 | 170 | 205 |
| Total Liabilities | 168 | 193 | 189 | 209 | 240 | 326 | 333 | 347 | 405 | 446 | 507 | 557 |
| Fixed Assets | 9 | 18 | 17 | 17 | 21 | 84 | 71 | 61 | 53 | 49 | 58 | 57 |
| CWIP | 0 | 0 | 0 | 6 | 34 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | 43 | 43 | 70 | 66 | 39 | 80 | 31 | 43 | 91 | 97 | 106 | 84 |
| Other Assets | 116 | 131 | 101 | 120 | 147 | 163 | 230 | 243 | 261 | 300 | 342 | 416 |
| Total Assets | 168 | 193 | 189 | 209 | 240 | 326 | 333 | 347 | 405 | 446 | 507 | 557 |
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operating Activity | 19 | 16 | 26 | 2 | 7 | 49 | -19 | 29 | 54 | 13 | 37 | -3 |
| Cash from Investing Activity | -12 | -5 | -20 | 2 | 3 | -77 | 52 | -8 | -43 | 1 | -20 | 18 |
| Cash from Financing Activity | -8 | -9 | -4 | -5 | -7 | 22 | -33 | -19 | -12 | -9 | -5 | -26 |
| Net Cash Flow | -1 | 2 | 2 | -1 | 3 | -5 | 0 | 2 | -2 | 5 | 12 | -12 |
| Free Cash Flow | 18 | 6 | 25 | -5 | -22 | 13 | -25 | 27 | 52 | 8 | 17 | -11 |
| CFO/OP | 96% | 78% | 149% | 49% | 56% | 232% | -20% | 80% | 130% | 42% | 78% | 16% |
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 88 | 84 | 100 | 109 | 85 | 96 | 90 | 102 | 118 | 107 | 119 | 113 |
| Inventory Days | 27 | 35 | 72 | 64 | 64 | 98 | 90 | 77 | 66 | 57 | 54 | 90 |
| Days Payable | 79 | 77 | 102 | 105 | 89 | 166 | 133 | 117 | 139 | 105 | 115 | 114 |
| Cash Conversion Cycle | 36 | 42 | 70 | 68 | 61 | 28 | 48 | 62 | 46 | 58 | 59 | 89 |
| Working Capital Days | 43 | 48 | 79 | 80 | 65 | -10 | 57 | 68 | 61 | 69 | 68 | 92 |
| ROCE % | 33% | 35% | 19% | 14% | 19% | 10% | 16% | 18% | 19% | 26% | 17% | 15% |
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Promoters | 70.59% | 69.94% | 69.91% | 69.91% | 69.91% | 69.91% | 69.91% | 69.91% | 71.81% | 71.81% | 71.79% | 71.79% |
| FIIs | 0.00% | 0.00% | 0.03% | 0.03% | 0.02% | 0.02% | 0.04% | 0.04% | 0.00% | 0.00% | 0.05% | 0.01% |
| DIIs | 0.00% | 0.00% | 0.10% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Public | 29.40% | 30.05% | 29.96% | 30.05% | 30.06% | 30.07% | 30.04% | 30.04% | 28.19% | 28.17% | 28.14% | 28.19% |
| No. of Shareholders | 19,066 | 20,519 | 22,237 | 23,494 | 23,910 | 24,279 | 24,235 | 24,257 | 28,250 | 27,889 | 27,425 | 27,484 |
Fundamentals
Market Cap₹ 897 Cr.
Current Price₹ 89.7
Stock P/E20.3
Book Value₹ 35.1
ROCE14.9 %
ROE10.7 %
Dividend Yield1.67 %
Face Value₹ 5.00
Compounded Sales Growth (TTM)10%
Compounded Profit Growth (TTM)-4%
Standalone figures.
Valuation
Market capRs 860 Cr
Enterprise valueRs 852 Cr
P/E (TTM)19.48x
Price to book2.44x
Price to sales1.10x
EV / EBITDA11.76x
EV / EBIT13.93x
EV / sales1.09x
Earnings yield5.13%
Dividend yield1.75%
P/E, 3-year average11.50x
P/B, 3-year average1.72x
P/E, 5-year average9.41x
P/B, 5-year average1.40x
Profitability
Operating margin (excl. other income)8.06%
Operating margin (incl. other income)8.63%
EBITDA margin9.30%
Pre-tax margin7.73%
Net profit margin5.67%
Net margin, latest quarter5.89%
ROE12.10%
ROCE16.01%
ROA7.72%
ROE, 3-year average16.67%
ROCE, 3-year average21.77%
ROA, 3-year average10.59%
ROE, 5-year average16.20%
ROCE, 5-year average21.11%
ROA, 5-year average10.08%
ROIC (approx.)13.46%
Tax rate24.29%
Other income / net worth1.24%
Growth
Sales growth (latest year)16.65%
Profit growth (latest year)-13.31%
Sales CAGR, 3 years13.52%
Sales CAGR, 5 years12.30%
Profit CAGR, 3 years4.30%
Profit CAGR, 5 years7.62%
Sales growth QoQ-4.11%
Profit growth QoQ-2.23%
Sales growth YoY (latest quarter)3.93%
Profit growth YoY (latest quarter)37.59%
Per share
EPS (TTM)Rs 4.41
EPS (latest year)Rs 4.10
EPS (latest quarter)Rs 1.14
EPS, 3-year averageRs 8.51
EPS, 5-year averageRs 7.77
Book value per shareRs 35.14
Sales per shareRs 77.72
Cash flow per shareRs -0.30
Free cash flow per shareRs -1.10
Dividend per share (latest year)Rs 1.50
Dividend per share, 3-year averageRs 1.83
Dividend per share, 5-year averageRs 1.85
Dividends
Dividend payout36.61%
Dividend payout, 3-year average24.45%
Dividend payout, 5-year average25.95%
Efficiency
Asset turnover1.38x
Fixed asset turnover13.63x
Inventory turnover4.42x
Inventory days83 days
Debtor days113 days
Debtors turnover3.23x
Creditor days114 days
Cash conversion cycle89 days
Working capital days92 days
Leverage
Total debtRs 0 Cr
Cash and bankRs 8 Cr
Net debtRs -8 Cr
Debt to equity0.00x
Net debt / EBITDA-0.11x
Interest coverage63.71x
Current ratio (filing 2026-03-31)2.22x
Quick ratio (filing 2026-03-31)1.50x
Trade payables (filing 2026-03-31)Rs 188 Cr
Owners' fund to total sources63.19%
Debt to assets0.01%
Cash flow
Cash from Operating Activity (latest year)Rs -3 Cr
Cash from Investing Activity (latest year)Rs 18 Cr
Cash from Financing Activity (latest year)Rs -26 Cr
Net Cash Flow (latest year)Rs -12 Cr
Free cash flow (latest year)Rs -11 Cr
FCFE (approx.: FCF + change in debt)Rs -22 Cr
Cash from ops / profit, 5 years0.60x
Statement figures
Net sales (TTM)Rs 779 Cr
Net sales (latest year)Rs 772 Cr
Sales (latest quarter)Rs 194 Cr
Operating profit excl. other income (latest year)Rs 62 Cr
Operating profit (latest quarter)Rs 16 Cr
Other income (TTM)Rs 5 Cr
EBITDA (TTM)Rs 72 Cr
PBDT (TTM)Rs 71 Cr
Profit before tax (TTM)Rs 60 Cr
Tax (latest year)Rs 13 Cr
Net profit (TTM)Rs 44 Cr
Net profit (latest year)Rs 41 Cr
Net profit (latest quarter)Rs 11 Cr
Depreciation (TTM)Rs 11 Cr
Depreciation (latest quarter)Rs 2 Cr
Interest (TTM)Rs 1 Cr
Cost of goods sold (latest year)Rs 653 Cr
Total expenditure (latest year)Rs 709 Cr
Total income (latest year)Rs 776 Cr
Share capitalRs 50 Cr
ReservesRs 302 Cr
Shareholders' fundsRs 352 Cr
Total assetsRs 557 Cr
Net blockRs 57 Cr
InvestmentsRs 84 Cr
ReceivablesRs 239 Cr
InventoryRs 148 Cr
Other liabilitiesRs 205 Cr
Shares outstanding (crore)10.02
Ownership
Promoter holding71.79% (+1.88 in a year)
Computed by MarketFriction from the standalone statements. Returns use average balances.
P/E 19.5 is at the 49th percentile of its own 9.4-year range
(median 19.5, low 11.9, high 69.7).
P/B 2.44 is at the 36th percentile (median 2.70).
Monthly. Market cap from split-adjusted price; profit and book value as reported by that month. A low percentile means cheap versus its own history, not cheap versus peers.
| Period | ANUHPHR | Nifty 50 | Difference |
|---|---|---|---|
| 1 week | -5.4% | -2.8% | -2.7 pts |
| 1 month | +5.4% | -6.8% | +12.2 pts |
| 3 months | +6.7% | -7.6% | +14.3 pts |
| 6 months | +28.1% | +0.4% | +27.7 pts |
| 1 year | +1.2% | -9.9% | +11.1 pts |
| 3 years | +32.1% | +14.2% | +17.9 pts |
| 5 years | +49.2% | +27.9% | +21.3 pts |
1 mutual fund schemes hold about ₹0 Cr.
Over three months 0 bought more and 1 sold (share counts, price move removed).
| Fund | Weight | Est. Cr | 3m shares |
|---|---|---|---|
| Bandhan BSE Healthcare Index Fund | 0.01% | 0 | -6% |
Red flags
F-score 4 of 8| explain | Weak cash conversion Cash from operations was 32% of net profit over the last 3 years |
| look | Inventory outrunning sales Inventory grew 98% vs sales +17% in 2026 |
Checks on the latest reported years: cash vs profit, accruals, receivables and inventory vs sales, dilution, debt, interest cover, equity, other income, losses, and auditor, top-management, insolvency and regulator filings in the last 12 months. A flag asks for an explanation; it is not a verdict.
Latest quarter
Jun 2026Sales ₹194 Cr +4.3% vs Jun 2025.
Net profit ₹11 Cr +37.5%.
Against our estimate for Jun 2026: sales -7.3%, profit +2.6% in line. Our estimate for Sep 2026: sales Rs 192 Cr, profit Rs 11 Cr (how).
Activity
Compare| Company | Mcap (Cr) | P/E | ROCE |
|---|---|---|---|
| Sun Pharmaceutical Industries Ltd | 447,476 | 35.4 | 20.5 % |
| Divis Laboratories Ltd | 250,363 | 84.0 | 22.0 % |
| Torrent Pharmaceuticals Ltd | 186,152 | 83.4 | 15.2 % |
| Zydus Lifesciences Ltd | 119,750 | 24.6 | 21.1 % |
| Cipla Ltd | 111,430 | 31.1 | 15.5 % |
| Laurus Labs Ltd | 106,928 | 97.8 | 17.8 % |
| Mankind Pharma Ltd | 105,120 | 49.3 | 13.5 % |
| Dr Reddys Laboratories Ltd | 104,494 | 32.4 | 13.0 % |
| Aurobindo Pharma Ltd | 97,682 | 25.8 | 12.9 % |
| Lupin Ltd | 93,840 | 15.8 | 29.9 % |
| Glenmark Pharmaceuticals Ltd | 68,905 | 22.1 | 39.8 % |
| Alkem Laboratories Ltd | 62,772 | 27.6 | 21.2 % |
| Biocon Ltd | 61,439 | 84.5 | 3.61 % |
| Abbott India Ltd | 57,949 | 35.9 | 44.8 % |
| Gland Pharma Ltd | 49,333 | 43.1 | 15.1 % |
No bulk or block deals on record.
| Ex-date | Action | Factor |
|---|---|---|
| 2026-08-05 | Dividend - Rs 1.50 Per Share | |
| 2025-08-14 | Dividend - Rs 1.50 Per Share | |
| 2025-07-15 | Bonus 1:1 | 0.5000 |
No announcements in our files yet.
Company filings to NSE, newest first. Routine notices (trading window, newspaper copies) are left out. Click a row for the filing.
No short selling reported to NSE in our files.
Short sales disclosed by brokers to NSE, by trade date. Collected since late September 2026.
Not on any NSE surveillance list in the latest file.
Quick answers
What is the market cap of Anuh Pharma Ltd?
Anuh Pharma Ltd (ANUHPHR) has a market capitalisation of Rs 897 Cr. at the 2026-10-01 close.
What is the P/E ratio of Anuh Pharma Ltd?
Anuh Pharma Ltd trades at a P/E of 20.3 on trailing twelve-month profit, at the 2026-10-01 close.
What were Anuh Pharma Ltd's latest quarterly results?
In the Jun 2026 quarter, Anuh Pharma Ltd sales was Rs 194 Cr (+4.3% vs Jun 2025) and net profit was Rs 11 Cr.
What is the 52-week high and low of Anuh Pharma Ltd?
The 52-week high is Rs 99.50 and the 52-week low is Rs 67.00.